Regorafenib and Sintilimab in combination with electroacupuncture
F-IRB-SOP-00710
Unknown small_molecule active
Quick answer
Regorafenib and Sintilimab in combination with electroacupuncture for Colorectal Cancer Metastatic is a Unknown program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Colorectal Cancer Metastatic
- Phase
- Unknown
- Modality
- small_molecule
- Status
- active